Möchten Sie immer auf dem neuesten Stand bleiben?

Pluvicto® PSMAddition oral presentation to highlight efficacy outcomes by disease volume and de novo/recurrent metastatic hormone-sensitive prostate cancerKisqali® NATALEE oral presentation to report...

Dublin, May 18, 2026 (GLOBE NEWSWIRE) -- The "Life Science Instrumentation Market by Technology, Application, End User - Global Forecast to 2031" has been added to ResearchAndMarkets.com's...

More durable, deeper PSA response in patients treated with Pluvicto plus standard of care (ARPI + ADT) vs. SoC aloneDeep PSA reduction higher in patients receiving Pluvicto combination vs. SoC at 12,...

Dublin, May 06, 2026 (GLOBE NEWSWIRE) -- The "Preclinical Imaging Industry Analysis, Size, Share, Growth, Trends, and Forecast 2026-2033 - (by Product Type, Application, End-User, Geographic...

Dublin, April 07, 2026 (GLOBE NEWSWIRE) -- The "Messenger RNA Market - A Global and Regional Analysis: Application and Regional Analysis - Analysis and Forecast, 2025-2035" has been added to ...

Facility expected to be operational in 2028 in Dallas-Fort Worth area, expanding largest RLT manufacturing network in USSite to serve patients in Southern US and add network capacity as RLT expands...

Facility expected to be operational in 2028 in Dallas-Fort Worth area, expanding largest RLT manufacturing network in USSite to serve patients in Southern US and add network capacity as RLT expands...

In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPCReal‑world evidence showed Pluvicto achieved longer PFS when initiated after one ARPI instead...

New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites including Cambridge, Massachusetts, and Basel,...

New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites including Cambridge, Massachusetts, and Basel,...